Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.

Authors:
Francesca Vena Ruochen Jia Arman Esfandiari Juan J Garcia-Gomez Manuel Rodriguez-Justo Jianguo Ma Sakeena Syed Lindsey Crowley Brian Elenbaas Samantha Goodstal John A Hartley Daniel Hochhauser

Oncotarget 2018 Feb 22;9(14):11592-11603. Epub 2018 Jan 22.

Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.

Targeting the DNA damage response (DDR) in tumors with defective DNA repair is a clinically successful strategy. The RAS/RAF/MEK/ERK signalling pathway is frequently deregulated in human cancers. In this study, we explored the effects of MEK inhibition on the homologous recombination pathway and explored the potential for combination therapy of MEK inhibitors with DDR inhibitors and a hypoxia-activated prodrug. We studied effects of combining pimasertib, a selective allosteric inhibitor of MEK1/2, with olaparib, a small molecule inhibitor of poly (adenosine diphosphate [ADP]-ribose) polymerases (PARP), and with the hypoxia-activated prodrug evofosfamide in ovarian and pancreatic cancer cell lines. Apoptosis was assessed by Caspase 3/7 assay and protein expression was detected by immunoblotting. DNA damage response was monitored with γH2AX and RAD51 immunofluorescence staining. antitumor activity of pimasertib with evofosfamide were assessed in pancreatic cancer xenografts. We found that BRCA2 protein expression was downregulated following pimasertib treatment under hypoxic conditions. This translated into reduced homologous recombination repair demonstrated by levels of RAD51 foci. MEK inhibition was sufficient to induce formation of γH2AX foci, suggesting that inhibition of this pathway would impair DNA repair. When combined with olaparib or evofosfamide, pimasertib treatment enhanced DNA damage and increased apoptosis. The combination of pimasertib with evofosfamide demonstrated increased anti-tumor activity in BRCA wild-type Mia-PaCa-2 xenograft model, but not in the BRCA mutated BxPC3 model. Our data suggest that targeted MEK inhibition leads to impaired homologous recombination DNA damage repair and increased PARP inhibition sensitivity in BRCA-2 proficient cancers.

Download full-text PDF

 Source
http://dx.doi.org/10.18632/oncotarget.24294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837749PMC
February 2018

Publication Analysis

Top Keywords

mek inhibition
16
dna damage
16
homologous recombination
12
pimasertib evofosfamide
8
pimasertib treatment
8
pancreatic cancer
8
hypoxia-activated prodrug
8
inhibition leads
8
protein expression
8
damage response
8
dna repair
8
dna
7
pimasertib
5
mek
5
inhibition
5
reduced homologous
4
activity pimasertib
4
translated reduced
4
antitumor activity
4
staining antitumor
4

Keyword Occurance

Similar Publications

Neoadjuvant Cytoreductive Treatment with BRAF/MEK Inhibition of prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single Arm, Open-label Phase II Trial.

Authors:
Stéphanie A Blankenstein Maartje W Rohaan W Martin C Klop Bernies van der Hiel Bart A van de Wiel Max J Lahaye Sandra Adriaansz Karolina Sikorska Harm van Tinteren Aysegül Sari Lindsay G Grijpink-Ongering Winan J van Houdt Michel W J M Wouters Christian U Blank Sofie Wilgenhof Johannes V van Thienen Alexander C J van Akkooi John B A G Haanen

Ann Surg 2021 Apr 9. Epub 2021 Apr 9.

Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands Department of Biometrics, Princes Máxima Centrum, Utrecht, the Netherlands Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.

Objective: To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in patients with unresectable locally advanced melanoma.

Summary Background Data: Approximately 5% of stage III melanoma patients presents with unresectable locally advanced disease, making standard of care with resection followed by adjuvant systemic therapy impossible. Although neoadjuvant targeted therapy has shown promising results in resectable stage III melanoma, its potency to enable surgical resection in patients with primarily unresectable locally advanced stage III melanoma is still unclear. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Management of Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives.

Authors:
Hiroyuki Takeda Yu Sunakawa

Front Oncol 2021 25;11:602194. Epub 2021 Mar 25.

Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan.

mutations constitute an important poor prognostic factor in metastatic colorectal cancer (mCRC) and the development of treatments in this context is of great necessity to prolong patient survival. Although the association between mutations and microsatellite instability (MSI) has been known for several years, previous clinical trials have revealed that the former has a limited prognostic impact and that immune checkpoint inhibitors offer a significant survival benefit to mCRC patients with both characteristics. Furthermore, the genomic classification of mutations according to their molecular functions enables greater understanding of the characteristics of mCRC patients with mutations, with therapeutic strategies based on this classification made more ideal to improve poor prognosis through the delivery of targeted therapies. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Enhancement of skin barrier and hydration-related molecules by protopanaxatriol in human keratinocytes.

Authors:
Jeong-Oog Lee So-Hyeon Hwang Ting Shen Ji Hye Kim Long You Weicheng Hu Jae Youl Cho

J Ginseng Res 2021 Mar 11;45(2):354-360. Epub 2020 Dec 11.

Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Korea.

Background: Protopanaxatriol (PPT) is a secondary intestinal metabolite of ginsenoside in ginseng. Although the effects of PPT have been reported in various diseases including cancer, diabetes and inflammatory diseases, the skin protective effects of PPT are poorly understood.

Methods: HaCaT cells were treated with PPT in a dose-dependent manner. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

MEK1/2 activity modulates TREM2 cell surface recruitment.

Authors:
Jason Schapansky Yelena Y Grinberg David M Osiecki Emily A Freeman Stephen G Walker Eric Karran Sujatha M Gopalakrishnan Robert V Talanian

J Biol Chem 2020 Dec 25;296:100218. Epub 2020 Dec 25.

AbbVie Inc, Cambridge Research Center, Cambridge, Massachusetts, USA.

Rare sequence variants in the microglial cell surface receptor TREM2 have been shown to increase the risk for Alzheimer's disease (AD). Disease-linked TREM2 mutations seem to confer a partial loss of function, and increasing TREM2 cell surface expression and thereby its function(s) might have therapeutic benefit in AD. However, druggable targets that could modulate microglial TREM2 surface expression are not known. Read More

View Article and Full-Text PDF
December 2020
Similar Publications

Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.

Authors:
Igor Odintsov Marissa S Mattar Allan J W Lui Michael Offin Christopher Kurzatkowski Lukas Delasos Inna Khodos Marina Asher Robert M Daly Natasha Rekhtman Elisa de Stanchina Gopinath Ganji Marc Ladanyi Romel Somwar

J Thorac Oncol 2021 Apr 8. Epub 2021 Apr 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Introduction: NRG1 rearrangements produce chimeric ligands that subvert the ERBB pathway to drive tumorigenesis. A better understanding of the signaling networks that mediate transformation by NRG1 fusions is needed to inform effective therapeutic strategies. However, this has been hampered by a paucity of patient-derived disease models that faithfully recapitulate this molecularly defined cancer subset. Read More

View Article and Full-Text PDF
April 2021
Similar Publications